Science Current Events | Science News | Brightsurf.com
 

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012
CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research


Related Bevacizumab Current Events and Bevacizumab News Articles


TGen-UCSF study in Neuro-Oncology provides comprehensive look at brain cancer treatments
Led by the Translational Genomics Research Institute (TGen) and UC San Francisco (UCSF), a comprehensive genetic review of treatment strategies for glioblastoma brain tumors was published today in the Oxford University Press journal Neuro-Oncology.

Allow NHS doctors to prescribe cheap, safe and effective sight loss drug, says The BMJ
NHS doctors should be allowed to prescribe a cheap, safe and effective drug for the degenerative eye disease, wet age related macular degeneration (AMD) - a leading cause of blindness among older patients, says an investigation by The BMJ today.

Tumor location in colorectal cancer may influence survival
The two halves of the human colon have different embryonic origins and gene expression patterns, and these differences may also play a role in cancer biology, according to a study published February 24 in the JNCI: Journal of the National Cancer Institute.

Breast Cancer Specialist Presents Positive Results for Triple-Negative Breast Cancer Presurgery Chemotherapy Benefits
A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.

Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs.

Adding cediranib to chemo improves progression-free survival for meta or recurrent cervical cancer
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

Cancer-fighting cocktail demonstrates promising results as new treatment for advanced cervical cancer
Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

Cheaper alternative to licensed drug for treating eye disease has similar side-effects
Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today.

Women & Infants Breast Cancer Specialist Reports Advance in Treatment of Triple-Negative Breast Cancer
William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women.

Hijacking the brain's blood supply: Tumor discovery could aid treatment
Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time.
More Bevacizumab Current Events and Bevacizumab News Articles

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer
by James Lee Anderson (Author)


“Although, your health condition may impact your everyday life, do not let it define who you are.” AVASTIN (Bevacizumab) injection is given with other medicines to treat patients with metastatic (a cancer that has spread) carcinoma of the colon or rectum. This medicine is also used to treat a certain type of metastatic lung cancer called nonsquamous, non-small cell lung cancer, and a certain type of brain tumor called glioblastoma. AVASTIN (Bevacizumab) is a substance that helps the body fight cancer. It prevents the growth of certain types of blood vessels to cancer cells. This helps to decrease the growth of cancer cells by starving the cells of nutrients that are needed to grow. AVASTIN (Bevacizumab) injection is also used in combination with other medicines (eg, interferon alfa)...

Bevacizumab: Webster's Timeline History, 2001 - 2007

Bevacizumab: Webster's Timeline History, 2001 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Bevacizumab," including when used in literature (e.g. all authors that might have Bevacizumab in their name). As such, this book represents the largest compilation of timeline events associated with Bevacizumab when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

  Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article): An article from: Family Practice News
by Jeff Evans (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on September 1, 2003. The length of the article is 1131 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article)
Author: Jeff Evans
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2003
Publisher: International Medical News Group
Volume: 33 Issue: 17 Page: 42(1)

Article Type: Brief Article

Distributed by Thomson...

  Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds): An article from: Internal Medicine News
by Jeff Evans (Author)


This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2003. The length of the article is 318 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds)
Author: Jeff Evans
Publication: Internal Medicine News (Magazine/Journal)
Date: October 1, 2003
Publisher: International Medical News Group
Volume: 36 Issue: 19 Page: 26(1)

Distributed by Thomson...

  Bevacizumab improves survival in patients with colorectal cancer.(Gastroenterology): An article from: Internal Medicine News
by International Medical News Group (Publisher)


This digital document is an article from Internal Medicine News, published by International Medical News Group on April 1, 2005. The length of the article is 530 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab improves survival in patients with colorectal cancer.(Gastroenterology)
Publication: Internal Medicine News (Magazine/Journal)
Date: April 1, 2005
Publisher: International Medical News Group
Volume: 38 Issue: 7 Page: 69(1)

Distributed by Thomson...

  Bevacizumab aids survival in breast, lung, colorectal cancer: antiangiogenesis agent appears effective.(News): An article from: Family Practice News
by Jane Salodof MacNeil (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on June 15, 2005. The length of the article is 1884 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab aids survival in breast, lung, colorectal cancer: antiangiogenesis agent appears effective.(News)
Author: Jane Salodof MacNeil
Publication: Family Practice News (Magazine/Journal)
Date: June 15, 2005
Publisher: International Medical News Group
Volume: 35 Issue: 12 Page: 1(2)

Distributed by Thomson...

  Bevacizumab improved survival in leading cancers.(Clinical Rounds): An article from: Skin & Allergy News
by Jane Salodof MacNeil (Author)


This digital document is an article from Skin & Allergy News, published by International Medical News Group on July 1, 2005. The length of the article is 1396 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab improved survival in leading cancers.(Clinical Rounds)
Author: Jane Salodof MacNeil
Publication: Skin & Allergy News (Magazine/Journal)
Date: July 1, 2005
Publisher: International Medical News Group
Volume: 36 Issue: 7 Page: 60(1)

Distributed by Thomson...

  Bevacizumab aids survival in cancer.(News): An article from: Internal Medicine News
by Jane Salodof MacNeil (Author)


This digital document is an article from Internal Medicine News, published by Thomson Gale on June 15, 2005. The length of the article is 1903 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab aids survival in cancer.(News)
Author: Jane Salodof MacNeil
Publication: Internal Medicine News (Magazine/Journal)
Date: June 15, 2005
Publisher: Thomson Gale
Volume: 38 Issue: 12 Page: 1(3)

Distributed by Thomson...

  Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine): An article from: Family Practice News
by Jane Salodof MacNeil (Author)


This digital document is an article from Family Practice News, published by Thomson Gale on September 1, 2006. The length of the article is 713 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine)
Author: Jane Salodof MacNeil
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2006
Publisher: Thomson Gale
Volume: 36 Issue: 17 Page: 43(1)

Distributed by Thomson...

  Bevacizumab: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed.
by Tish, A. M. Davidson (Author)


Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures.

© 2015 BrightSurf.com